Which has preferable valuation and earnings, BBNX or AXGN?

AxoGen has higher revenue and earnings than Beta Bionics. AxoGen is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Beta Bionics $110.24M 5.53 -$73.20M -$1.51 N/A AxoGen $225.21M 10.55 -$15.70M -$0.64 N/A

Is BBNX or AXGN more profitable?

AxoGen has a net margin of -13.21% compared to Beta Bionics' net margin of -60.27%. AxoGen's return on equity of -9.63% beat Beta Bionics' return on equity. Company Net Margins Return on Equity Return on Assets Beta Bionics -60.27% -23.00% -20.55% AxoGen -13.21% -9.63% -6.26%

Does the media refer more to BBNX or AXGN?

In the previous week, Beta Bionics had 2 more articles in the media than AxoGen. MarketBeat recorded 5 mentions for Beta Bionics and 3 mentions for AxoGen. AxoGen's average media sentiment score of 1.61 beat Beta Bionics' score of 1.06 indicating that AxoGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beta Bionics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AxoGen 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to BBNX or BFLY?

In the previous week, Butterfly Network had 5 more articles in the media than Beta Bionics. MarketBeat recorded 10 mentions for Butterfly Network and 5 mentions for Beta Bionics. Beta Bionics' average media sentiment score of 1.06 beat Butterfly Network's score of 0.36 indicating that Beta Bionics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beta Bionics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Butterfly Network 1 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer LMAT or BBNX?

In the previous week, Beta Bionics had 2 more articles in the media than LeMaitre Vascular. MarketBeat recorded 5 mentions for Beta Bionics and 3 mentions for LeMaitre Vascular. Beta Bionics' average media sentiment score of 1.06 beat LeMaitre Vascular's score of -0.12 indicating that Beta Bionics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LeMaitre Vascular 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Beta Bionics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, NVCR or BBNX?

Beta Bionics has lower revenue, but higher earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NovoCure $655.35M 2.50 -$136.23M -$1.53 N/A Beta Bionics $110.24M 5.53 -$73.20M -$1.51 N/A

Is NVCR or BBNX more profitable?

NovoCure has a net margin of -25.66% compared to Beta Bionics' net margin of -60.27%. Beta Bionics' return on equity of -23.00% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets NovoCure -25.66% -50.82% -16.48% Beta Bionics -60.27% -23.00% -20.55%

Does the media prefer NVCR or BBNX?

In the previous week, NovoCure had 14 more articles in the media than Beta Bionics. MarketBeat recorded 19 mentions for NovoCure and 5 mentions for Beta Bionics. Beta Bionics' average media sentiment score of 1.06 beat NovoCure's score of 0.01 indicating that Beta Bionics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 5 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Beta Bionics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Beta Bionics (BBNX) Competitors

$13.67 -0.03 (-0.22%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$14.00 +0.33 (+2.41%)

As of 05:52 AM Eastern

Compare

BBNX vs. AXGN, BFLY, LMAT, PLSE, and NVCR

Should you buy Beta Bionics stock or one of its competitors? MarketBeat compares Beta Bionics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Beta Bionics include AxoGen (AXGN), Butterfly Network (BFLY), LeMaitre Vascular (LMAT), Pulse Biosciences (PLSE), and NovoCure (NVCR). These companies are all part of the "medical equipment" industry.

How does Beta Bionics compare to AxoGen?

Beta Bionics (NASDAQ:BBNX) and AxoGen (NASDAQ:AXGN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability.

80.3% of AxoGen shares are held by institutional investors. 5.3% of Beta Bionics shares are held by company insiders. Comparatively, 2.4% of AxoGen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

AxoGen has a net margin of -13.21% compared to Beta Bionics' net margin of -60.27%. AxoGen's return on equity of -9.63% beat Beta Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-60.27%	-23.00%	-20.55%
AxoGen	-13.21%	-9.63%	-6.26%

In the previous week, Beta Bionics had 2 more articles in the media than AxoGen. MarketBeat recorded 5 mentions for Beta Bionics and 3 mentions for AxoGen. AxoGen's average media sentiment score of 1.61 beat Beta Bionics' score of 1.06 indicating that AxoGen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beta Bionics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AxoGen	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Beta Bionics has a beta of 3.4, indicating that its stock price is 240% more volatile than the broader market. Comparatively, AxoGen has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market.

Beta Bionics presently has a consensus price target of $19.70, indicating a potential upside of 44.11%. AxoGen has a consensus price target of $46.50, indicating a potential upside of 4.05%. Given Beta Bionics' higher possible upside, analysts plainly believe Beta Bionics is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

AxoGen has higher revenue and earnings than Beta Bionics. AxoGen is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$110.24M	5.53	-$73.20M	-$1.51	N/A
AxoGen	$225.21M	10.55	-$15.70M	-$0.64	N/A

Summary

AxoGen beats Beta Bionics on 11 of the 17 factors compared between the two stocks.

How does Beta Bionics compare to Butterfly Network?

Beta Bionics (NASDAQ:BBNX) and Butterfly Network (NYSE:BFLY) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

Beta Bionics has a net margin of -60.27% compared to Butterfly Network's net margin of -73.63%. Beta Bionics' return on equity of -23.00% beat Butterfly Network's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-60.27%	-23.00%	-20.55%
Butterfly Network	-73.63%	-34.41%	-23.91%

Beta Bionics has higher revenue and earnings than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$110.24M	5.53	-$73.20M	-$1.51	N/A
Butterfly Network	$102.92M	19.03	-$77.06M	-$0.30	N/A

Beta Bionics has a beta of 3.4, meaning that its stock price is 240% more volatile than the broader market. Comparatively, Butterfly Network has a beta of 2.22, meaning that its stock price is 122% more volatile than the broader market.

37.8% of Butterfly Network shares are owned by institutional investors. 5.3% of Beta Bionics shares are owned by insiders. Comparatively, 22.0% of Butterfly Network shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Beta Bionics currently has a consensus target price of $19.70, indicating a potential upside of 44.11%. Butterfly Network has a consensus target price of $5.56, indicating a potential downside of 27.67%. Given Beta Bionics' stronger consensus rating and higher probable upside, research analysts clearly believe Beta Bionics is more favorable than Butterfly Network.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Butterfly Network	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Butterfly Network had 5 more articles in the media than Beta Bionics. MarketBeat recorded 10 mentions for Butterfly Network and 5 mentions for Beta Bionics. Beta Bionics' average media sentiment score of 1.06 beat Butterfly Network's score of 0.36 indicating that Beta Bionics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beta Bionics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Butterfly Network	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Beta Bionics beats Butterfly Network on 12 of the 17 factors compared between the two stocks.

How does Beta Bionics compare to LeMaitre Vascular?

LeMaitre Vascular (NASDAQ:LMAT) and Beta Bionics (NASDAQ:BBNX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation.

LeMaitre Vascular presently has a consensus price target of $112.60, indicating a potential upside of 22.46%. Beta Bionics has a consensus price target of $19.70, indicating a potential upside of 44.11%. Given Beta Bionics' higher probable upside, analysts plainly believe Beta Bionics is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

In the previous week, Beta Bionics had 2 more articles in the media than LeMaitre Vascular. MarketBeat recorded 5 mentions for Beta Bionics and 3 mentions for LeMaitre Vascular. Beta Bionics' average media sentiment score of 1.06 beat LeMaitre Vascular's score of -0.12 indicating that Beta Bionics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LeMaitre Vascular	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Beta Bionics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LeMaitre Vascular has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$249.60M	8.42	$57.73M	$2.71	33.93
Beta Bionics	$110.24M	5.53	-$73.20M	-$1.51	N/A

LeMaitre Vascular has a net margin of 24.35% compared to Beta Bionics' net margin of -60.27%. LeMaitre Vascular's return on equity of 15.36% beat Beta Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	24.35%	15.36%	9.78%
Beta Bionics	-60.27%	-23.00%	-20.55%

84.6% of LeMaitre Vascular shares are owned by institutional investors. 7.4% of LeMaitre Vascular shares are owned by insiders. Comparatively, 5.3% of Beta Bionics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

LeMaitre Vascular has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market. Comparatively, Beta Bionics has a beta of 3.4, meaning that its stock price is 240% more volatile than the broader market.

Summary

LeMaitre Vascular beats Beta Bionics on 11 of the 16 factors compared between the two stocks.

How does Beta Bionics compare to Pulse Biosciences?

Pulse Biosciences (NASDAQ:PLSE) and Beta Bionics (NASDAQ:BBNX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

77.0% of Pulse Biosciences shares are held by institutional investors. 74.0% of Pulse Biosciences shares are held by company insiders. Comparatively, 5.3% of Beta Bionics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Pulse Biosciences has higher earnings, but lower revenue than Beta Bionics. Pulse Biosciences is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350K	5,131.43	-$72.78M	-$1.10	N/A
Beta Bionics	$110.24M	5.53	-$73.20M	-$1.51	N/A

In the previous week, Beta Bionics had 5 more articles in the media than Pulse Biosciences. MarketBeat recorded 5 mentions for Beta Bionics and 0 mentions for Pulse Biosciences. Beta Bionics' average media sentiment score of 1.06 beat Pulse Biosciences' score of 0.00 indicating that Beta Bionics is being referred to more favorably in the news media.

Company	Overall Sentiment
Pulse Biosciences	Neutral
Beta Bionics	Positive

Pulse Biosciences has a net margin of 0.00% compared to Beta Bionics' net margin of -60.27%. Beta Bionics' return on equity of -23.00% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	N/A	-86.67%	-73.61%
Beta Bionics	-60.27%	-23.00%	-20.55%

Pulse Biosciences presently has a consensus target price of $30.67, indicating a potential upside of 18.18%. Beta Bionics has a consensus target price of $19.70, indicating a potential upside of 44.11%. Given Beta Bionics' stronger consensus rating and higher possible upside, analysts clearly believe Beta Bionics is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

Pulse Biosciences has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market. Comparatively, Beta Bionics has a beta of 3.4, meaning that its stock price is 240% more volatile than the broader market.

Summary

Beta Bionics beats Pulse Biosciences on 11 of the 17 factors compared between the two stocks.

How does Beta Bionics compare to NovoCure?

NovoCure (NASDAQ:NVCR) and Beta Bionics (NASDAQ:BBNX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

NovoCure currently has a consensus target price of $26.86, indicating a potential upside of 90.07%. Beta Bionics has a consensus target price of $19.70, indicating a potential upside of 44.11%. Given NovoCure's higher probable upside, research analysts plainly believe NovoCure is more favorable than Beta Bionics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

In the previous week, NovoCure had 14 more articles in the media than Beta Bionics. MarketBeat recorded 19 mentions for NovoCure and 5 mentions for Beta Bionics. Beta Bionics' average media sentiment score of 1.06 beat NovoCure's score of 0.01 indicating that Beta Bionics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	5 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Beta Bionics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NovoCure has a net margin of -25.66% compared to Beta Bionics' net margin of -60.27%. Beta Bionics' return on equity of -23.00% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-25.66%	-50.82%	-16.48%
Beta Bionics	-60.27%	-23.00%	-20.55%

84.6% of NovoCure shares are owned by institutional investors. 5.5% of NovoCure shares are owned by company insiders. Comparatively, 5.3% of Beta Bionics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Beta Bionics has lower revenue, but higher earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35M	2.50	-$136.23M	-$1.53	N/A
Beta Bionics	$110.24M	5.53	-$73.20M	-$1.51	N/A

NovoCure has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, Beta Bionics has a beta of 3.4, suggesting that its stock price is 240% more volatile than the broader market.

Summary

Beta Bionics beats NovoCure on 10 of the 17 factors compared between the two stocks.

Get Beta Bionics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BBNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BBNX vs. The Competition

Export

Metric	Beta Bionics	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$610.50M	$7.05B	$6.44B	$12.38B
Dividend Yield	N/A	1.27%	2.69%	5.83%
P/E Ratio	-9.05	48.65	24.66	23.99
Price / Sales	5.53	76.50	528.55	106.76
Price / Cash	N/A	24.78	44.82	54.51
Price / Book	2.09	7.13	10.83	6.50
Net Income	-$73.20M	$159.20M	$3.56B	$336.88M
7 Day Performance	3.64%	-1.92%	0.93%	-0.16%
1 Month Performance	15.65%	-2.88%	0.36%	0.76%
1 Year Performance	-13.04%	4.79%	29.66%	28.49%

Beta Bionics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BBNX Beta Bionics	3.543 of 5 stars	$13.67 -0.2%	$19.70 +44.1%	-13.5%	$610.50M	$110.24M	N/A	294	Positive News
AXGN AxoGen	1.9486 of 5 stars	$44.84 flat	$46.50 +3.7%	+356.5%	$2.38B	$225.21M	N/A	450	Positive News
BFLY Butterfly Network	1.2759 of 5 stars	$8.85 -0.6%	$5.56 -37.2%	+275.1%	$2.25B	$97.61M	N/A	460	Gap Down High Trading Volume
LMAT LeMaitre Vascular	4.6299 of 5 stars	$93.95 flat	$112.60 +19.9%	+10.3%	$2.15B	$249.60M	34.67	490	High Trading Volume
PLSE Pulse Biosciences	1.9394 of 5 stars	$25.60 flat	$30.67 +19.8%	+67.5%	$1.77B	$350K	N/A	140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BBNX) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Beta Bionics (BBNX) Competitors

BBNX vs. AXGN, BFLY, LMAT, PLSE, and NVCR

How does Beta Bionics compare to AxoGen?

Summary

How does Beta Bionics compare to Butterfly Network?

Summary

How does Beta Bionics compare to LeMaitre Vascular?

Summary

How does Beta Bionics compare to Pulse Biosciences?

Summary

How does Beta Bionics compare to NovoCure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBNX vs. The Competition

Beta Bionics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Beta Bionics (BBNX) Competitors

BBNX vs. AXGN, BFLY, LMAT, PLSE, and NVCR

How does Beta Bionics compare to AxoGen?

Do institutionals and insiders have more ownership in BBNX or AXGN?

Is BBNX or AXGN more profitable?

Does the media refer more to BBNX or AXGN?

Which has more volatility and risk, BBNX or AXGN?

Do analysts rate BBNX or AXGN?

Which has preferable valuation and earnings, BBNX or AXGN?

Summary

How does Beta Bionics compare to Butterfly Network?

Is BBNX or BFLY more profitable?

Which has stronger earnings and valuation, BBNX or BFLY?

Which has more risk & volatility, BBNX or BFLY?

Do insiders and institutionals believe in BBNX or BFLY?

Do analysts recommend BBNX or BFLY?

Does the media refer more to BBNX or BFLY?

Summary

How does Beta Bionics compare to LeMaitre Vascular?

Do analysts prefer LMAT or BBNX?

Does the media prefer LMAT or BBNX?

Which has stronger valuation & earnings, LMAT or BBNX?

Is LMAT or BBNX more profitable?

Do institutionals & insiders believe in LMAT or BBNX?

Which has more risk & volatility, LMAT or BBNX?

Summary

How does Beta Bionics compare to Pulse Biosciences?

Do insiders & institutionals have more ownership in PLSE or BBNX?

Which has higher earnings & valuation, PLSE or BBNX?

Does the media favor PLSE or BBNX?

Is PLSE or BBNX more profitable?

Do analysts recommend PLSE or BBNX?

Which has more volatility and risk, PLSE or BBNX?

Summary

How does Beta Bionics compare to NovoCure?

Do analysts recommend NVCR or BBNX?

Does the media prefer NVCR or BBNX?

Is NVCR or BBNX more profitable?

Do insiders & institutionals believe in NVCR or BBNX?

Which has higher earnings and valuation, NVCR or BBNX?

Which has more risk and volatility, NVCR or BBNX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBNX vs. The Competition

Beta Bionics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools